Impact of sarcopenia on survival of pancreatic cancer patients treated with concurrent chemoradiotherapy

Won Kyung Cho; Jeong Il Yu; Hee Chul Park; Do Hoon Lim; Tae Hyun Kim; Eui Kyu Chie

doi:10.1177/0300891620937795

Impact of sarcopenia on survival of pancreatic cancer patients treated with concurrent chemoradiotherapy

Won Kyung Cho
, Jeong Il Yu
, Hee Chul Park
, Do Hoon Lim
, Tae Hyun Kim
, Eui Kyu Chie

Department of Radiation Oncology

Sungkyunkwan University
National Cancer Center Korea
Seoul National University

Research output: Contribution to journal › Article › peer-review

18 Scopus citations

Abstract

Purpose: To investigate the prognostic impact of sarcopenia on the survival of patients with locally advanced pancreatic cancer (LAPC) treated with concurrent chemoradiotherapy (CCRT). Methods: We retrospectively reviewed 299 patients diagnosed with LAPC and treated with definitive CCRT from 2000 to 2015. Skeletal muscle index (SMI) was measured using computed tomography scans and sarcopenia was defined as SMI <29.6 cm²/m² for women and <36.2 cm²/m² for men. The significance of sarcopenia for progression-free survival (PFS) and overall survival (OS) was evaluated. Results: Sarcopenia was present in 29 patients (9.7%). In multivariate analysis, sarcopenia was a significant factor for PFS (p = 0.043). Although sarcopenia was not a significant factor for OS (p = 0.121) in multivariate analysis, long-term survivors were observed only in the no sarcopenia group (OS at 60 months: 9.5% vs 0%, p < 0.001). Conclusion: In patients undergoing CCRT for LAPC, sarcopenia is an independent factor for adverse prognosis.

Original language	English
Pages (from-to)	247-253
Number of pages	7
Journal	Tumori
Volume	107
Issue number	3
DOIs	https://doi.org/10.1177/0300891620937795
State	Published - Jun 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Pancreatic cancer
radiotherapy
sarcopenia

Access to Document

10.1177/0300891620937795

Cite this

@article{d5fd0574e5c94cc6b8b983208dd9cefb,

title = "Impact of sarcopenia on survival of pancreatic cancer patients treated with concurrent chemoradiotherapy",

abstract = "Purpose: To investigate the prognostic impact of sarcopenia on the survival of patients with locally advanced pancreatic cancer (LAPC) treated with concurrent chemoradiotherapy (CCRT). Methods: We retrospectively reviewed 299 patients diagnosed with LAPC and treated with definitive CCRT from 2000 to 2015. Skeletal muscle index (SMI) was measured using computed tomography scans and sarcopenia was defined as SMI <29.6 cm2/m2 for women and <36.2 cm2/m2 for men. The significance of sarcopenia for progression-free survival (PFS) and overall survival (OS) was evaluated. Results: Sarcopenia was present in 29 patients (9.7\%). In multivariate analysis, sarcopenia was a significant factor for PFS (p = 0.043). Although sarcopenia was not a significant factor for OS (p = 0.121) in multivariate analysis, long-term survivors were observed only in the no sarcopenia group (OS at 60 months: 9.5\% vs 0\%, p < 0.001). Conclusion: In patients undergoing CCRT for LAPC, sarcopenia is an independent factor for adverse prognosis.",

keywords = "Pancreatic cancer, radiotherapy, sarcopenia",

author = "Cho, \{Won Kyung\} and Yu, \{Jeong Il\} and Park, \{Hee Chul\} and Lim, \{Do Hoon\} and Kim, \{Tae Hyun\} and Chie, \{Eui Kyu\}",

note = "Publisher Copyright: {\textcopyright} Fondazione IRCCS Istituto Nazionale dei Tumori 2020.",

year = "2021",

month = jun,

doi = "10.1177/0300891620937795",

language = "English",

volume = "107",

pages = "247--253",

journal = "Tumori",

issn = "0300-8916",

publisher = "Wichtig Publishing Srl",

number = "3",

}

TY - JOUR

T1 - Impact of sarcopenia on survival of pancreatic cancer patients treated with concurrent chemoradiotherapy

AU - Cho, Won Kyung

AU - Yu, Jeong Il

AU - Park, Hee Chul

AU - Lim, Do Hoon

AU - Kim, Tae Hyun

AU - Chie, Eui Kyu

N1 - Publisher Copyright: © Fondazione IRCCS Istituto Nazionale dei Tumori 2020.

PY - 2021/6

Y1 - 2021/6

N2 - Purpose: To investigate the prognostic impact of sarcopenia on the survival of patients with locally advanced pancreatic cancer (LAPC) treated with concurrent chemoradiotherapy (CCRT). Methods: We retrospectively reviewed 299 patients diagnosed with LAPC and treated with definitive CCRT from 2000 to 2015. Skeletal muscle index (SMI) was measured using computed tomography scans and sarcopenia was defined as SMI <29.6 cm2/m2 for women and <36.2 cm2/m2 for men. The significance of sarcopenia for progression-free survival (PFS) and overall survival (OS) was evaluated. Results: Sarcopenia was present in 29 patients (9.7%). In multivariate analysis, sarcopenia was a significant factor for PFS (p = 0.043). Although sarcopenia was not a significant factor for OS (p = 0.121) in multivariate analysis, long-term survivors were observed only in the no sarcopenia group (OS at 60 months: 9.5% vs 0%, p < 0.001). Conclusion: In patients undergoing CCRT for LAPC, sarcopenia is an independent factor for adverse prognosis.

AB - Purpose: To investigate the prognostic impact of sarcopenia on the survival of patients with locally advanced pancreatic cancer (LAPC) treated with concurrent chemoradiotherapy (CCRT). Methods: We retrospectively reviewed 299 patients diagnosed with LAPC and treated with definitive CCRT from 2000 to 2015. Skeletal muscle index (SMI) was measured using computed tomography scans and sarcopenia was defined as SMI <29.6 cm2/m2 for women and <36.2 cm2/m2 for men. The significance of sarcopenia for progression-free survival (PFS) and overall survival (OS) was evaluated. Results: Sarcopenia was present in 29 patients (9.7%). In multivariate analysis, sarcopenia was a significant factor for PFS (p = 0.043). Although sarcopenia was not a significant factor for OS (p = 0.121) in multivariate analysis, long-term survivors were observed only in the no sarcopenia group (OS at 60 months: 9.5% vs 0%, p < 0.001). Conclusion: In patients undergoing CCRT for LAPC, sarcopenia is an independent factor for adverse prognosis.

KW - Pancreatic cancer

KW - radiotherapy

KW - sarcopenia

UR - https://www.scopus.com/pages/publications/85087761464

U2 - 10.1177/0300891620937795

DO - 10.1177/0300891620937795

M3 - Article

C2 - 32646298

AN - SCOPUS:85087761464

SN - 0300-8916

VL - 107

SP - 247

EP - 253

JO - Tumori

JF - Tumori

IS - 3

ER -

Impact of sarcopenia on survival of pancreatic cancer patients treated with concurrent chemoradiotherapy

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this